Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Extract

Neutrophil gelatinase-associated lipocalin (NGAL) is the first member of a new generation of diagnostics called ‘renal biomarkers’ that may be just a few steps away from entering clinical practice. What does this new test measure? Is this the new ‘troponin for the kidney’? What are the most important conclusions from clinical studies on NGAL? What are their limitations? How will NGAL affect clinical practice? Nephrologists will soon encounter these questions more frequently. Hence, in this editorial, we will attempt to briefly summarize the current state of the NGAL field.

NGAL, a small 25-kDa protein of the lipocalin family, was discovered through a genome-wide analysis of kidney genes that are induced in response to experimental acute kidney injury (AKI) in animals [1]. NGAL was among the top upregulated genes in damaged kidneys and fulfilled the criteria of a promising biomarker of tubular damage since it was a secreted tubular protein that entered both urine and serum rapidly after the onset of AKI. Markedly, increased levels of NGAL in blood and urine could be detected following ischaemia-reperfusion injury in mice [1]. The early preclinical studies prompted a large and rapidly expanding body of clinical trials that addressed the utility of NGAL in diagnosing AKI. Studies in patients undergoing cardiopulmonary bypass revealed marked increases of plasma and urinary NGAL levels as early as 2 h after surgery in patients that developed AKI [2,3]. This increase in NGAL preceded the increase in serum creatinine by 24–48 h. Similar increases in NGAL levels were observed in other clinical settings, including contrast-induced AKI, sepsis-associated AKI and AKI following kidney transplantation [4–7]. Furthermore, several studies suggested that elevated NGAL levels are predictive of poor clinical outcomes in AKI, including dialysis initiation and mortality, even when adjusted for conventional predictors, such as creatinine levels [2,8–10].

Issue Section:
Editorial Comments
You do not currently have access to this article.
Download all slides

Comments

0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.